Sitting, from left, are Kinectrics president John D’Angelo CCTE COO and Milan Shah. Standing, from left, are Nuclear New Build vice president Sean Donnelly, CCTE executive advisor Paul Thompson, and CCTE CTO Paul Chan. (Photo: Clean Core)
Clean Core Thorium Energy announced that BWX Technologies–owned Kinectrics will conduct an independent technical review of its ANEEL (Advanced Nuclear Energy for Enriched Life) fuel qualification program.
According to CCTE, Kinectrics will review key aspects of the fuel design, manufacturing, safety, and regulatory readiness.
Bruce's Unit 7 is now producing Lutetium-177, used in targeted cancer therapeutics. (Photo: Bruce Power)
An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of lutetium-177 using Unit 7 of the Bruce nuclear power plant in Kincardine, Ontario. According to the companies, this marks the first time a commercial power reactor has been used to commercially produce short-lived medical radioisotopes.
The new IPS installed in Bruce Power’s Unit 7 will produce Lu-177 for treating cancer. (Photo: Bruce Power)
An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.